Drugs / AZD5004
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT07444424 | Mar → Jul 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT07455825 | Mar → Jun 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06988553 | Jun → Nov 2025 | obesity disorder, type 2 diabetes mellitus | Eccogene | Completed | No outcome recorded |
| Phase 1 | NCT06942936 | May 2025 → Jan 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06996886 | May → Jul 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06948747 | May → Oct 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06857695 | Mar → May 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06813781 | Dec 2024 → Oct 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06742762 | Dec 2024 → Apr 2025 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06703658 | Nov 2024 → Mar 2025 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06555822 | Aug 2024 → Mar 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06579105 | Oct 2024 → Dec 2025 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-02-10 | Eccogene | Results Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China eccogene.com ↗
The results demonstrated a safety and tolerability profile consistent with the GLP-1 receptor agonist (GLP-1RA) class. |
| 2022-11-03 | Eccogene | Regulatory Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004 eccogene.com ↗
Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2 diabetes mellitus (T2DM). |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06742762 ↗ |
| Route | Oral | “Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.” NCT06555822 ↗ |